ReviewCancer management and research2020

Ipilimumab and Nivolumab as First-Line Treatment of Patients with Renal Cell Carcinoma: The Evidence to Date.

Iris Y Sheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.